Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Schizophrenia is a debilitating chronic condition that affects approximately 1 % of Americans, who experience symptoms such as hallucinations, delusions, and disorders of thought and movement. These symptoms are described as positive symptoms, because they are experienced in addition to what healthy individuals experience. Negative symptoms, which are reductions in normal functioning, and cognitive deficits, which are problems in thinking, also plague people with schizophrenia. The negative symptoms and cognitive deficits associated with schizophrenia are produced in otherwise healthy people by neurotransmitters inhibiting the glutamatergic N-methyl-d-aspartate NMDA receptors in the brain. This inhibition of NMDA receptors also causes intensification of psychotic symptoms in otherwise stabilized schizophrenic patients. The drug D-cycloserine partially excites NMDA receptors, and it has been used to help patients with anxiety disorders to overcome phobias while they are receiving cognitive behavioral therapy. This study will examine whether D-cycloserine can increase the cognitive flexibility of someone undergoing CBT and thereby enhance the therapy's ability to reduce a patient's belief in paranoid delusions, preoccupation with delusions, and related distress.
All participants will be screened to ensure proper diagnosis of schizophrenia without other conditions. Those who pass will be randomly assigned to receive either D-cycloserine first or a placebo pill first. One week after the screening, participants in the D-cycloserine group will be given the drug before a 1-hour session of simulated CBT treatment. Those in the placebo condition will receive a placebo pill before an identical session. Two weeks after the screening, both groups will be called back for another session of CBT, but the pills they receive will be switched. Those who received D-cycloserine the first week will receive placebo, and those who received placebo will receive D-cycloserine. The CBT sessions will attempt to increase cognitive flexibility in patients by asking them to provide alternate explanations for common situations. At screening, at the start of visits on the first and second weeks, and at a follow-up visit on the third week, participants will undergo a series of assessments, including interviews, computerized tests, and self-report measures. Belief in, preoccupation with, and distress caused by delusions, as well as degree of cognitive flexibility, will be assessed.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- MGH Schizophrenia Program - Freedom Trail Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meets DSM-IV criteria for schizophrenia, schizoaffective disorder, or schizophrenia, paranoid subtype, based on chart review, Structured Clinical Interview for DSM-IV, and consultation with the patient's clinicians
- Medicated with an antipsychotic agent other than clozapine at a stable dose for at least 6 weeks
- Scores at least 3, or "moderate," on the Scale for the Assessment of Positive Symptoms global delusion rating
- Paranoid or referential delusional content
- Never engaged in formal CBT psychotherapy in the past
Exclusion Criteria:
- Diagnosis of a comorbid Axis I disorder other than schizophrenia
- Active substance abuse or dependence within 6 months
- Significant suicidal ideation within 6 weeks
- Pregnant or nursing
- Unstable medical disorder
- impaired renal clearance (creatinine <60mg/dL/min)
- Suffering from dementia
- Suffering from seizure disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1 D-cycloserine, placebo
Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
|
Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
Other Names:
One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
Other Names:
|
|
Experimental: 2 Placebo, D-cycloserine
Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
|
Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
Other Names:
One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Alternative Beliefs Assessment
Time Frame: Baseline to Week 2
|
Number of alternative beliefs generated on the Alternative Beliefs Assessment.
This assessment used nine vignettes describing social interactions: three of neutral content, three negatively-valanced, and three tailored to the patient's specific delusions.
Participants were asked to generate as many explanations (alternative beliefs) as they could for each scenario, and the number of explanations produced in response to each item was recorded.
Scores could range from 0 to as many explanations a person could produce (no maximum value).
The total score was calculated by adding all alternative beliefs generated from each vignette.
A higher number of alternative beliefs generated reflects a greater degree of cognitive flexibility.
|
Baseline to Week 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Psychotic Rating Scales (PSYRATS) Delusion Score
Time Frame: Baseline to Week 2
|
The Delusions subscale is a 6 item clinician administered scale, with Likert items 0-4 and range is 0-24.
Higher scores represent worse outcomes
|
Baseline to Week 2
|
|
Change in Beck Cognitive Insight Scale (BCIS)
Time Frame: Baseline to Week 2
|
The BCIS is a 15-item self-report scale with Likert items 0-3. It consists of a composite score, where higher scores represent better outcomes, and there are 2 subscales: 1) Self-Reflectiveness (higher scores represent better outcomes) and 2) Self-Certainty (higher scores represent worse outcomes). The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty. Step 1. Score every item on the BCIS from "0" to "3" according to the following rule: "Do Not Agree at All" = 0, "Agree Slightly" = 1, "Agree a Lot" = 2, "Agree Completely" = 3 Step 2. Calculate self-reflectiveness subscale: sum items 1, 3, 4, 5, 6, 8, 12, 14, and 15. Step 3. Calculate self-certainty subscale: sum items 2, 7, 9, 10, 11, and 13. Step 4. Calculate BCIS composite index: self-reflectiveness minus self-certainty. |
Baseline to Week 2
|
|
Change in Bead Task Score Measuring Probabilistic Reasoning
Time Frame: Baseline to Week 2
|
The Bead task is a reasoning task, where the number of beads guessed is the numeric value represented in the data.
The lower end range is 1, and there is no upper range limit.
Higher scores represent better outcomes.
|
Baseline to Week 2
|
|
Change in the Maudsley Assessment of Delusions Scale
Time Frame: Baseline to Week 2
|
This scale is a one-question item added on to the Bead Task.
The one item asks for a certainty rating, from 1-3.
Higher scores represent better outcomes.
|
Baseline to Week 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Donald C. Goff, MD, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P50MH060450 (U.S. NIH Grant/Contract)
- 2P50MH060450-07A1 (U.S. NIH Grant/Contract)
- DATR A3-NSC (National Institute of Mental Health)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.